IBA signs contract with partner CGN Medical Technology for the installation of a ProteusPLUS system in China

This contract is the second order from CGN Medical Technology for IBA’s ProteusPLUS system

Louvain-La-Neuve, Belgium, June 13, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announced it has signed an equipment contract with its partner CGN Medical Technology (CGNMT) for IBA’s ProteusPLUS¹ proton therapy system,  with one gantry treatment room to be installed at the West China International Cancer Treatment Center in Chengdu, Sichuan Province.

CGNMT is the sole proton therapy system vendor for West China International Cancer Treatment Center in Chengdu. Following the strategic licensing agreement signed between IBA and CGNNT in 2020, IBA provides the key components of the ProteusPLUS system to CGNMT which will be installed at the hospital site. CGNMT will be responsible for the installation, commissioning, service and maintenance of the proton therapy equipment.
                                                                                                               
Olivier Legrain, Chief Executive Officer of IBA, commented: “This project is the ninth ProteusPLUS system to be installed in China and the second order received from CGNMT since the beginning of our successful collaboration. We were happy to meet the management team of CGNMT in person for the first time since the pandemic and the signature of our agreement. We have been impressed with the progress that has been made so far by our partner and look forward to continuing our relationship with them to ensure the future success and expansion of proton therapy in the Chinese market.”